Biocon India is an Indian biopharmaceutical company based in Bangalore, India. The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in the developed markets of the United States and Europe. It also manufactures biosimilar insulins, which are sold in India as branded formulations and in both bulk and formulation forms.
With the dynamics of the pharma world shifting, emerging markets —the 17 high-growth pharmaceutical markets, particularly Brazil— present an important opportunity for biotechnology firms. Biocon has entered into partnerships with companies around the world to gain access in emerging markets